drugset / Trial / NCT02220296
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.
Timeline
- Start
- 2014-08-20
- Primary completion
- 2015-03-31
- Completion
- 2015-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin 338 | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.4 iu/kg | Subcutaneous |